WGSJefferies isn’t blinking
GeneDx keeps running into the same investor question: is the genetic testing market getting crowded, or is there still a lot of room to grow? Jefferies basically answered with a shrug and a Buy rating, along with a $150 price target — a pretty big vote of confidence for a stock trading around $67.76.
The bull case: more room than it looks
The firm’s message was simple: market penetration concerns may be overcooked. In other words, Jefferies thinks GeneDx can still expand without immediately bumping into a wall of saturation. That matters because when a stock has already moved, investors start hunting for reasons the party has to end. Jefferies is saying, not so fast.
Not the only one in the room
This wasn’t a one-note chorus either. The article also points to a few other recent calls:
- BTIG cut its price target from $200 to $170, but kept a Buy rating
- Piper Sandler reiterated Overweight with a $130 target
- The company also recently hosted its fourth-quarter earnings call and reaffirmed prior results while guiding for 2026
So yeah, the Street isn’t exactly singing in perfect harmony — but the overall tune is still pretty upbeat.
Why you should care
When analysts keep reiterating bullish ratings, it can help shore up sentiment even if the stock is already expensive relative to its recent price. For GeneDx, the next big question is whether growth keeps outrunning the saturation story. If it does, today’s price targets may start looking conservative fast.
Big picture: analysts are still betting GeneDx has more upside left in the tank, which is exactly the kind of thing that can keep a momentum stock humming.